



## Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series

June 19, 2025

MORRISTOWN, N.J., June 19, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that Dave Lennon, PhD, President and CEO, and David Dornan, PhD, Chief Scientific Officer, will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, June 26, 2025, at 10 AM ET.

To register in advance, please use this [link](#). A live webcast of the event can be accessed by visiting the "Investors & News" page on the Whitehawk Therapeutics [website](#) and will be available for replay for approximately 30 days following the event.

### About Whitehawk Therapeutics

Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at [www.whitehawktx.com](http://www.whitehawktx.com) and connect with us on LinkedIn.

### Contact

[IR@whitehawktx.com](mailto:IR@whitehawktx.com)



View original content to download multimedia: <https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-hc-wainwright-hcwhome-series-302485848.html>

SOURCE Whitehawk Therapeutics, Inc.